Predicting Colorectal Cancer Recurrence and Patient Survival Using Supervised Machine Learning Approach: A South African Population-Based Study

Okechinyere J. Achilonu 1*, June Fabian 2,3, Brendan Bebington 3,4, Elvira Singh 1,5, M. J. C. Eijkemans 6 and Eustasius Musenge 1,7

 Background: South Africa (SA) has the highest incidence of colorectal cancer (CRC) in Sub-Saharan Africa (SSA). However, there is limited research on CRC recurrence and survival in SA. CRC recurrence and overall survival are highly variable across studies. Accurate prediction of patients at risk can enhance clinical expectations and decisions within the South African CRC patients population. We explored the feasibility of integrating statistical and machine learning (ML) algorithms to achieve higher predictive performance and interpretability in findings.

 Methods: We selected and compared six algorithms:- logistic regression (LR), naïve Bayes (NB), C5.0, random forest (RF), support vector machine (SVM) and artificial neural network (ANN). Commonly selected features based on OneR and information gain, within 10-fold cross-validation, were used for model development. The validity and stability of the predictive models were further assessed using simulated datasets.

 Results: The six algorithms achieved high discriminative accuracies (AUC-ROC). ANN achieved the highest AUC-ROC for recurrence (87.0%) and survival (82.0%), and other models showed comparable performance with ANN. We observed no statistical difference in the performance of the models. Features including radiological stage and patient’s age, histology, and race are risk factors of CRC recurrence and patient survival, respectively.

 Conclusions: Based on other studies and what is known in the field, we have affirmed important predictive factors for recurrence and survival using rigorous procedures. Outcomes of this study can be generalised to CRC patient population elsewhere in SA and other SSA countries with similar patient profiles.

 Keywords: colorectal, cancer, recurrence, survival, machine learning, filter feature selection, prediction
1. INTRODUCTION

Colorectal cancer (CRC) is the third most common cancer, and the fourth cause of cancer-related death (1). Approximately 2 million cases of CRC were diagnosed globally in 2018. The CRC incidence significantly varies, with high-income countries having a higher risk of CRC than low-middle-income countries (LMICs). However, this may not be the true reflection of the burden of cancer in LMICs due to the lack of cancer registries in most LMICs (2). CRC is steadily rising in LMICs because of the adoption of western lifestyle (3). South Africa (SA) has the highest incidence of CRC in sub-Saharan Africa, and CRC is among the most commonly diagnosed cancer in South African men, and women (4). In 2018, the age-standardised incidence rate of CRC in SA was 18.1 and 12.0 per 100,000 population of men and women, respectively (3).

Accurate prognosis of cancer outcomes can provide helpful knowledge to clinicians, which is critical in making informed decisions that can improve patient care. Several efforts have been invested in improving the accuracy of cancer outcome predictions both at the data level, and algorithmic level (5). The advancement in the amount of medical data generated in cancer research has enabled the development of various artificial intelligence and machine learning (ML) expert systems. In data mining (DM), these systems are used to identify risk factors that can support medical decisions in cancer prognosis. ML algorithms are built upon the foundation of statistical learning, but with fewer assumptions (6). Unlike statistical models, ML algorithms avoid the hurdles in accurately modelling the data-generating process and estimating the feature coefficients. Also, ML models are designed to automatically handle noise in a dataset, complex interaction, non-linearity, large sample size and features. Overall, ML algorithms have been shown to improve treatment outcome in cancer research (5, 7). However, ML only focuses on optimising the predictive performance rather than transparency and interpretability (7). Hence, ML and statistical models can be used concurrently to achieve both clarity and higher predictive power.

Several predictive models have been published in the area of CRC recurrence and survivability prediction using the concept of statistical and ML algorithms. Nan et al. (8) conducted a retrospective study on elderly patients with CRC, using a Cox proportional hazard model. These patients were followed for more than 5 years, and different optimal treatment methods were given to them. Their findings suggest that patient features such as age, treatment methods, lymph node metastasis, histology type, Dukes stage and degree of differentiation should be considered when planning a patient’s treatment method. Using a support vector machine (SVM) algorithm, Ting et al. (9) highlighted that features including age, tumour size, pathologic stage, smoking, alcohol consumption, organisational patterns, BMI are important predictive factors for CRC recurrence. In the prediction of a 5-year CRC patient-specific survival outcome, Bychkov et al. (10) developed a deep learning-based classifier directly from small digitised tumour tissue samples. Although with an area under the curve of receiving operating classification (AUC) of 69%, the deep learning classification outperformed the predictive classification accuracy achieved by a pathologist assessment, with more prognostic information. Previous studies have shown that factors affecting CRC recurrence and patients survival with CRC are not fully understood. These factors vary across studies due to differences in geographical locations, lifestyle and available patient records.

Overall, several clinical information, modelling strategies, and algorithms have been employed in the CRC predictive studies (9–13). Algorithms including SVM, artificial neural network (ANN), random forest (RF), C5.0, Naïve Bayes (NB) and logistic regression (LR) have shown good performance in predicting survivability and recurrence of CRC (11, 13, 14). Nonetheless, there is no optimal model in the literature, and most of the developed models are yet to be validated. Hence, there exists a necessity to develop a South African model that can identify risk factors influencing CRC recurrence or survival and serves as a helping hand for specialists in personalising patients’ medical regimen. This study predicted CRC recurrence and survivability outcomes using C5.0, LR, RF, NB, SVM, and ANN. Our aims were to (i) quantify and compare the performance of these algorithms using both established and local information on the CRC patient database, (ii) identify features that have predictive value on CRC patient recurrence and survival, and (iii) evaluate the reliability and stability of the model performance using different simulated data. Thus, this study will form the basis of other studies in developing a South African model for CRC prognostic prediction.

2. MATERIALS AND METHODS

2.1. Study Population

The Colorectal Cancer in South Africa (CRCSA) study was the first prospective study designed to describe the clinical presentation, demographics, risk factors, treatment, and outcomes according to population group, from both private and state health–care facilities in Johannesburg, SA (2). This study was officially launched in January 2016. This study aimed to describe the clinical features and outcomes of adults presenting with histologically confirmed primary adenocarcinoma of the colon and rectum in a multi-ethnic urban population in Johannesburg. Participants over the age of 18 years with CRC within the previous 12 months were eligible. A total number of 716 patients were recruited from 2015 and were followed up at 6 months intervals from the date of recruitment, with the last follow up to the 31st of March 2020. Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), Chris Hani Baragwanath Academic Hospital (CHBAH), Wits Donald Gordon Medical Centre (WDGMC), and Edenvale Hospital that serve as private and public hospitals to many urban dwellers in the Johannesburg metropole were used as the study sites. However, the database for the CRC study was curated at WDGMC; hence, we referred to this study data as WDGMC CRC data. Questionnaires and scoring systems were used for the baseline assessments at these sites. Patient information included demographics, socio-economic status, dietary history, family history of cancer, medical and surgical history, colonoscopy,
histopathological diagnosis, recurrence and survival histories. The design and methodology of the study data are detailed in Bebington et al. (2). In collaboration with authors in Bebington et al. (2), the present study was approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (M1911131).

2.2. Predictive Model Development and Validation
Basic descriptive statistics were performed to describe the characteristics of the WDGMC CRC data for the continuous and categorical features in the dataset. Eighty-eight (88) features were identified in the CRC dataset based on previous studies and expert opinion. Several data pre-processing steps were performed to reduce algorithm-deployment time and improve the quality and efficiency of our findings. The pattern of missing values within the features was assessed, and Supplementary Figure 1 shows that the feature “reason for the use of chemotherapy” has the highest proportion of missing values. The Little MCAR test showed that the missingness in the data was completely random ($p = 0.306$). MissForest method of imputation (15) was used to impute the missing values in the WDGMC CRC data. This method of imputation has successfully been applied in different fields of research, including our recent study (16), with minimum error in both the continuous and categorical features. A total number of 696 patients were selected for analysis after data pre-processing. Two variations of the WDGMC data were used in this study to model recurrence and survivability. The first outcome feature (recurrence) is a binary categorical variable, where the class values indicate disease recurrence (264 cases) or non-recurrence (433 controls), irrespective of whether it is a local or distant recurrence. The second outcome feature (survivability) is also a binary categorical variable with values “survived” (399 controls) or “not-survived” (281 cases). Sixteen patients that were censored during the follow-up were further dropped in the survival modelling because their outcome status is unknown.

Some of the identified features may not have an impact on the outcome variables in this study. Also, we understand that over-fitting a predictive model may affect its ability to generalise in other settings. To reduce the chances of over-fitting the classifiers, we considered reducing the number of study features. A systematic combination of univariate (Information gain and One Rule) and multivariate (Least Absolute Shrinkage and Selection Operator) feature selection methods were applied in this study. Information gain (IG) and One Rule (OneR) are filtering approaches with good performance reported in different practice settings (17, 18). These algorithms assign a score to each feature to indicate its impact on the outcome. The Least Absolute Shrinkage and Selection Operator (LASSO) fit a model containing all the study features and uses a regularisation process to penalise the coefficients of the predictors, thereby shrinking features that have no impact on the outcome to zero (19).

A two-level feature selection method was proposed. We aimed to select and rank the top ten features for the univariate selection methods in the first level. For the LASSO method, we identified features with non-zero coefficients after the shrinking process. Common features selected in the first level were combined in the second level selection and were used as input features for the classifiers. It should be noted that this step was internally conducted within 10-fold cross-validation (CV) to give all the predictor features a fair advantage of being selected (Figure 1). In this procedure, the algorithms iterate 10-times over the study dataset. In each round, the dataset was split into 10-folds: 1-fold for validation and the remaining $k − 1$ folds (nine folds) for training the model. The training-folds were used for the model establishment, while the testing fold was used to test the generalisability of the model.

We used LR, NB, C5.0, RF, SVM, and ANN algorithms for predictive analytics (20–23). For all the models implemented in this study, SVM gave the highest execution time of 29.02 s. Simulation studies were used to assess the stability and validity of the developed models (24). The simulation scenarios aimed to mimic the distribution of the WDGMC CRC data, based on the features used to develop the predictive models for recurrence and survival. The area under the curve of receiving operating characteristics (AU-ROC) was used to assess the performance differences among the classifiers based on the AU-ROC scores (25). A comprehensive description of the simulation methodologies, the selected algorithms and the parameters used in the model development is in the (Supplementary 1, 2 and Supplementary Table 2). We have also documented and shared the R codes used for all the analysis reported in this manuscript through Github (https://github.com/KechJay/ML_RSPM) for model reproducibility. However, only the synthetic data is included in this link, and the WDGMC data will be made available on request.

3. RESULTS
3.1. Patient Characteristics and Feature Selection
The median length of follow-up for survival was approximately 11 months. Analysis of the demographics characteristics shows that the study was a predominance of black patients (356, 51%). Of this number, 154 (43%) experienced CRC recurrence, while 185 (52%) patients died. Among the 246 (35%) white patients, there were 78 (32%) recorded recurrence and 68 (28%) deaths. The remaining 95 (14%) patients (grouped as “others”) include Asians and mixed race. The records show that 32 (34%) of these group had occurred CRC, while 28 (29%) of the total died before the end of the study. It was observed that 44% of the male patients (364) died and 39% had recurrent cancer. Approximately 37% of the percentage of female patients (333) died or had CRC recurrence. The average age of the participants was 57 years, with a range of 18–91 years. Other features used in the modelling procedures are also described in Table 1.

Table 1 also shows the best combination of features based on the three methods of feature selection for recurrence and survival outcomes. Under the univariate techniques, the ranking
scores of these features show the importance of each feature to the outcome. For instance, the two methods indicate that having adenocarcinoma or non-adenocarcinoma (based on histology report) is the most relevant feature for survival. This feature was not selected by any of these methods under recurrence. The most important feature selected by these methods under recurrence is the stage of CRC malignancy. CRC staging was also selected by these methods as an important feature for recurrence. The LASSO method shows the coefficients of the selected features, indicating their effects on the outcomes at $\lambda = 0.032$, where $\lambda$ is the tuning parameter that controls the degree of penalty.

The ranking of the importance of the selected features according to the different predictive models is shown in Tables 2, 3. Although all the features have contributed to the model developments, there is no consistency in the feature ranking across the predictive models. For the CRC recurrence modelling, the top-ranked features based on the models include “radiological stage”, “age at 1st visit”, “chemotherapy” and “hospital”. Also, “histology”, “radiological stage”, “CRC complication” is among the most important features for CRC survival (Table 3). We used LR to estimate the effects of these features on the outcome variables. The odds ratios are shown in Figures 2A,B for recurrence and survival, respectively. The figures show that some of these features negatively influence CRC recurrence or survival. For instance, we observed that the odds of CRC recurrence are reduced by 51% for those patients recruited at the public hospitals compared with patients recruited at the private hospital. The radiological stage, among other features, significantly increases the odds of CRC recurrence and survival. It is shown that the odds of CRC recurrence at stage IV is about 10 times higher than the odds when CRC is at stages I and II. We also observed that the odds of death at stage IV is more than twice the odds of death at stages I and II. Nevertheless, some of these important features used for the development of CRC recurrence or survival model show no significant effect on the outcomes (at 5% level of significance) according to LR.

3.2. Model Predictive Performances for Recurrence and Survival Outcomes

Table 4 shows that all the resulting models had AU-ROC above 0.85. ANN demonstrated the highest performance with discriminating scores of 0.87 (CI: 0.835–0.905). It should be noted that the confidence interval of the models do not include the 50% chance ($y = x$), indicating that these models are significantly better than chance. The least predictive performance for the CRC recurrence was achieved by NB (0.854, CI: 0.819–0.890). Even though the ANN had the highest AU-ROC value, pairwise comparisons of the model performances show no significant difference between ANN and the other models. The results of the stability assessment using simulated data are also shown in Table 4. All the AU-ROC scores for the different predictive models achieved more than 90% discriminative accuracy in predicting CRC recurrence. ANN maintained higher predictive performance across the three simulated datasets. In the same manner, the ANN has the highest AU-ROC value in predicting survival (0.818, CI: 0.781–0.856) as shown in Table 5. Other predictive models achieved AU-ROC curves higher than 80%, with RF and SVM showing the least performance scores. There was no significant difference when these models were compared. It is observed that all the predictive models across the simulated data show comparable estimates. Furthermore, the models show comparable performance in predicting recurrence and survival, based on the accuracy metric (Supplementary Table 3).

4. DISCUSSION

In this study strategy, we imputed a few cells with missing information in the data to maximise the cases in the analysis. The idea of selecting the best common features based on the systematic combination of univariate and multivariate feature selection methods optimised the accuracy of the prediction models. This was done to minimise the chances of over-fitting by not crowding the algorithms with too many features (27). Reducing the cost of measuring several features for a specific outcome, mainly when fewer features can be used to represent others, is the goal of prediction modelling. When we incorporated the features that were not commonly identified by the feature selection method, the models’ performances decreased compared to when the commonly identified features were used. This underscores the significance of systematically employing more than one feature selection method in this type of analysis.
TABLE 1 | Characteristics of the WDGMC population based on the selected features from information gain, OneR, and LASSO.

| Feature                  | Total (%) | Description                                      | Recurrence outcome | Survival outcome |
|--------------------------|-----------|--------------------------------------------------|--------------------|-----------------|
|                          |           |                                                  | IG     | OneR  | LASSO  | IG    | OneR  | LASSO  |
| Age at 1st visit         | 57 (13)   | Age at the time of first visit                   | 0.022  | 0.621 | -0.010 | 0.042 | 0.567 | 0.009  |
| Race                     |           | Race                                             | 0.042  | 0.567 | 0.009  | 0.127 | 0.755 | -2.527 |
| Black                    | 356 (51.1)|                                                  |                    |                  |        |        |        |
| White                    | 246 (35.3)|                                                  |                    |                  |        |        |        |
| Others                   | 96 (13.6) |                                                  |                    |                  |        |        |        |
| Histology                |           | Histology                                        | 0.127  | 0.755 | -2.527 | 0.018  | 0.621 | -0.111 |
| Adenocarcinoma           | 430 (61.7)|                                                  | 0.098  | 0.708 | -0.732 | 0.075  | 0.659 | 0.284  |
| Others                   | 267 (38.6)|                                                  |                    |                  |        |        |        |
| CRC complications        |           | cancer related complication                      | 0.036  | 0.908 | -2.527 | 0.018  | 0.621 | -0.111 |
| No                       | 310 (44.5)|                                                  | 0.098  | 0.708 | -0.732 | 0.075  | 0.659 | 0.284  |
| Yes                      | 387 (55.5)|                                                  | 0.087  | 0.715 | 0.232  | 0.018  | 0.621 | -0.111 |
| Procedure                |           | Did patient undergo any procedure listed          | 0.031  | 0.641 | -0.006 | 0.087  | 0.715 | 0.232  |
| Yes                      | 410 (58.8)|                                                  | 0.087  | 0.715 | 0.232  | 0.018  | 0.621 | -0.111 |
| No                       | 287 (41.2)|                                                  | 0.031  | 0.641 | -0.006 | 0.087  | 0.715 | 0.232  |
| Hospital                 |           | Study site of recruitment                        | 0.018  | 0.621 | -0.111 | 0.018  | 0.621 | -0.111 |
| Private                  | 248 (35.6)|                                                  | 0.075  | 0.659 | 0.284  | 0.060  | 0.645 |        |
| Public                   | 449 (66.4)|                                                  | 0.087  | 0.715 | 0.232  |        |        |        |
| Language                 |           | What is your home language                        | 0.018  | 0.621 | -0.111 | 0.060  | 0.645 | 0.018  |
| English                  | 241 (34.6)|                                                  | 0.062  | 0.673 |        | 0.062  | 0.673 |        |
| Indigenous African language | 326 (46.8)|                                                  | 0.062  | 0.673 |        | 0.062  | 0.673 |        |
| Others                   | 130 (18.7)|                                                  | 0.062  | 0.673 |        | 0.062  | 0.673 |        |
| Radiological stage       |           | Assessment of stage of malignancy                | 0.141  | 0.781 | 0.062  | 0.794  |        |        |
| Unable to stage          | 80 (11.5) |                                                  | 0.000  | 0.794 |        | 0.000  | 0.794 |        |
| Stage I and II           | 157 (22.5)|                                                  | 0.000  | 0.794 |        | 0.000  | 0.794 |        |
| Stage III                | 240 (34.4)|                                                  | -0.023 | 0.783 |        | 0.000  | 0.794 |        |
| Stage IV                 | 220 (31.6)|                                                  | 2.055   | 1.472 |        | 1.316  |        |        |
| Recurrence status        |           | Did patient cancer recur after the follow-up     | 0.037  | 0.648 | 1.700  | 0.037  | 0.648 | 1.700  |
| Recurrence               | 433 (62.1)|                                                  | 0.037  | 0.648 | 1.700  |        |        |        |
| Non-recurrence           | 264 (37.9)|                                                  | 0.037  | 0.648 | 1.700  |        |        |        |
| Chemotherapy             |           | Receipt of chemotherapy                           | 0.051  | 0.683 | 0.884  | 0.051  | 0.683 | 0.884  |
| Yes                      | 246 (35.3)|                                                  | 0.051  | 0.683 | 0.884  | 0.051  | 0.683 | 0.884  |
| No                       | 451 (64.7)|                                                  | 0.051  | 0.683 | 0.884  | 0.051  | 0.683 | 0.884  |
| Treatment decision       |           | Treatment decision, MDT1                         | 0.049  | 0.686 | 0.475  | 0.049  | 0.686 | 0.475  |
| Chemotherapy             | 214 (30.7)|                                                  | 0.049  | 0.686 | 0.475  | 0.049  | 0.686 | 0.475  |
| No chemotherapy          | 483 (69.3)|                                                  | 0.049  | 0.686 | 0.475  | 0.049  | 0.686 | 0.475  |
| Prior CRC treatment      |           | What previous treatment was given for this of patients colorectal cancer prior to recruitment | 0.028  | 0.666 | 1.205  | 0.018  | 0.651 | 0.594  |
| Surgical                 | 68 (10.0) |                                                  | 0.028  | 0.666 | 1.205  | 0.018  | 0.651 | 0.594  |
| Non-surgical             | 629 (90.0)|                                                  | 0.028  | 0.666 | 1.205  | 0.018  | 0.651 | 0.594  |
| CRC prior to recruit     |           | Was this colorectal cancer diagnosed prior to recruitment | 0.018  | 0.651 | 0.594  | 0.018  | 0.651 | 0.594  |
| Yes                      | 112 (16.1)|                                                  | 0.018  | 0.651 | 0.594  | 0.018  | 0.651 | 0.594  |
| No                       | 585 (83.9)|                                                  | 0.018  | 0.651 | 0.594  | 0.018  | 0.651 | 0.594  |
| Prior colonoscopy        |           | Colonoscopy done prior to first visit to the colorectal unit | 0.023  | 0.634 | 0.157  | 0.023  | 0.634 | 0.157  |
| Yes                      | 451 (64.7)|                                                  | 0.023  | 0.634 | 0.157  | 0.023  | 0.634 | 0.157  |
| No                       | 246 (35.3)|                                                  | 0.023  | 0.634 | 0.157  | 0.023  | 0.634 | 0.157  |

Our findings agree with Hastie et al. (28) that feature selection before cross-validation may result in a selection bias that could impact the predictive performance of a model. We observed differences in selection and performance before and within the 10-fold CV, which supported the study by Hastie et al. (28). A 10-fold CV was employed to improve the reliability of study.
the resultant estimates from the classifiers. This CV method was considered because the sample size is relatively small, and this method has been reported to provide the best trade-off between bias and variance in a relatively small dataset. The resultant estimates from the classifiers. This CV method was considered because the sample size is relatively small, and this method has been reported to provide the best trade-off between bias and variance in a relatively small dataset.

We found that these models demonstrated a high and comparable predictive ability (based on the AU-ROC) and showed no significant difference in their performance. Our findings recommend that all these models be considered in modelling CRC recurrence and survival. The two statistical methods (NB and LR) were as robust as ML predictive models, irrespective of the complexity of the ML algorithms. Our study correlates with other studies that found no significant difference between LR and ANN or SVM (30, 31). Studies on CRC recurrence and survival have used different prediction strategies such as modelling only rectal or colon, individual stage of CRC, year of survival, different features and modelling procedures. Our study used data from all stages of CRC, incorporating all the survival years in the data. Performance may not be directly compared; however, our predictive models discriminated reasonably well, both in recurrence and survival, and achieved AU-ROC values comparable to other CRC studies (9–13).

The concept of model validation through data simulation shows that the algorithms could identify the signals correlated with the outcome features. The simulated data over-simplified the artificial signal, which improves the models’ performance compared to the real (WDGMC) datasets. Moreover, the stability and validity of the model predictions across the different simulated samples provided empirical evidence that supports the results of the real data. Besides, when the artificial signals were removed from the simulated data, the discriminative ability of the algorithms deteriorated because patient risk (of “survived” or “not survived”) became less separable. This supports the evidence that predictive models can be compromised negatively in the absence of signal in a dataset (24).

We revealed several local and established risk factors for CRC recurrence and survival. Most of the factors, including CRC grading, gender, marital status and education level, etc., significantly influence the outcomes univariately. However, we aim to develop our model with a set of features (risk factors) that could significantly influence the outcomes. Hence, only features that were commonly selected in the modelling procedures were incorporated into the predictive models. Recurrence is a well-known risk factor that influences the survival of CRC patients (32). Our study shows that patients who experienced recurrence had poorer survival than patients who did not have a recurrence. “Radiological stage” is an important feature in this study, which significantly influences recurrence and survival. Specifically, “stage IV” CRC (when compared with the combination of “stages I” and “II”) increases the chances of recurrence or death. Studies, including Nan et al. (8), reported stage IV CRC patients to have a poor prognosis. A previous study reported that younger patients (<50 years) with CRC experienced higher recurrence compared to older patients but have a comparable rate of survival (33). This corresponds with our study, which shows that the odds of

TABLE 2 | Risk factor ranking in descending order showing the relative importance of each feature to modelling WDGMC CRC recurrence as ranked by each predictive models.

| Rank | LR | NB | C5.0 | RF | SVM | ANN |
|------|----|----|------|----|-----|-----|
| 1    | Radiologic stage | Radiologic stage | Prior colonoscopy | Radiologic stage | Radiologic stage | Age at 1st visit |
| 2    | Chemotherapy | Chemotherapy | Radiologic stage | Age at 1st visit | Chemotherapy | Treatment decision |
| 3    | Hospital | Treatment decision | Age at 1st visit | Chemotherapy | Treatment decision | Radiologic stage |
| 4    | Treatment decision | Procedure | Chemotherapy | Treatment decision | Procedure | Procedure |
| 5    | Age at 1st visit | Age at 1st visit | Treatment decision | Hospital | Age at 1st visit | CRC prior to recruit |
| 6    | Prior colonoscopy | Prior colonoscopy | Procedure | Prior colonoscopy | Prior CRC treatment | Treatment decision |
| 7    | Procedure | CRC prior to recruit | Prior CRC treatment | Hospital | Prior colonoscopy | Hospital |
| 8    | Prior CRC treatment | Prior CRC treatment | CRC prior to recruit | Hospital | CRC prior to recruit | Hospital |
| 9    | CRC prior to recruit | Hospital | CRC prior to recruit | Hospital | CRC prior to recruit | Hospital |

TABLE 3 | Risk factor ranking in descending order showing the relative importance of each feature to modelling WDGMC CRC survival as ranked by each predictive models.

| Rank | LR | NB | C5.0 | RF | SVM | ANN |
|------|----|----|------|----|-----|-----|
| 1    | Histology | Histology | Histology | Histology | Histology | CRC complications |
| 2    | Recurrence status | CRC complications | Hospital | Radiological stage | Radiological stage | Radiological stage |
| 3    | Hospital | Procedure | Radiological stage | Recurrence status | CRC complications | Recurrence status |
| 4    | Radiological stage | Hospital | Language | Procedure | Language | Language |
| 5    | CRC complications | Language | CRC complications | Recurrence status | CRC complications | Procedure |
| 6    | Procedure | Recurrence status | Race | Procedure | Race | Race |
| 7    | Race | Race | Procedure | Race | Race | Language |
recurrence slightly decreases with an increase in age. The age-related disparity is a well-documented fact and has been linked to factors such as a late-stage diagnosis and lifestyle (33, 34).

The type of CRC cancer is another important risk factor that significantly influences the survival outcome. The importance of this factor was affirmed in previous studies including Nan et al. (8) and Stojadinovic et al. (35). Our study indicates that patients with adenocarcinoma-type CRC had a reduced survival rate compared with patients presented with non-adenocarcinoma CRC. The impact of the recruitment site on recurrence or survival has been noted in the result section. A recent study in SA showed improved survival for CRC patients treated in private hospitals (36). However, this study was not extrapolated to CRC patients that were managed in public hospitals. Our findings support an improved survival for patients treated in a private hospital compared to those treated in public hospitals. These observed survival differences could be linked to the fact that most patients in public hospitals are relatively poor with lower
TABLE 4 | AU-ROC performance scores (with confidence interval) examining the consistency of the predictive models from the WDGMC CRC recurrence data and across the three simulated datasets used for model validation.

| Model | WDGMC (N = 697) | Sim.Data (N = 697) | Sim.Data (N = 3,485) | Sim.Data (N = 6,970) |
|-------|-----------------|-------------------|--------------------|---------------------|
|       | AUC (95% CI)    | AUC (95% CI)      | AUC (95% CI)       | AUC (95% CI)        |
| LR    | 0.861 (0.840–0.890) | 0.941 (0.919–0.964) | 0.923 (0.917–0.930) | 0.927 (0.922–0.932) |
| NB    | 0.854 (0.819–0.890) | 0.932 (0.908–0.965) | 0.925 (0.917–0.933) | 0.925 (0.921–0.929) |
| C5.0  | 0.867 (0.831–0.903) | 0.929 (0.904–0.954) | 0.937 (0.931–0.943) | 0.945 (0.943–0.948) |
| RF    | 0.863 (0.828–0.898) | 0.931 (0.905–0.967) | 0.933 (0.925–0.941) | 0.945 (0.941–0.949) |
| SVM   | 0.867 (0.833–0.900) | 0.940 (0.918–0.963) | 0.923 (0.916–0.930) | 0.930 (0.907–0.963) |
| ANN   | 0.870 (0.835–0.905) | 0.955 (0.940–0.971) | 0.947 (0.942–0.951) | 0.953 (0.949–0.958) |

TABLE 5 | AU-ROC performance scores (with confidence interval) examining the consistency of the predictive models from the WDGMC CRC survival data and across the three simulated datasets used for model validation.

| Model | WDGMC (N = 680) | Sim.Data (N = 680) | Sim.Data (N = 3,400) | Sim.Data (N = 6,800) |
|-------|-----------------|-------------------|--------------------|---------------------|
|       | AUC (95% CI)    | AUC (95% CI)      | AUC (95% CI)       | AUC (95% CI)        |
| LR    | 0.816 (0.776–0.856) | 0.912 (0.893–0.930) | 0.907 (0.897–0.916) | 0.911 (0.905–0.918) |
| NB    | 0.811 (0.771–0.850) | 0.907 (0.891–0.923) | 0.904 (0.893–0.914) | 0.907 (0.901–0.914) |
| C5.0  | 0.811 (0.771–0.855) | 0.902 (0.886–0.917) | 0.906 (0.897–0.914) | 0.911 (0.904–0.918) |
| RF    | 0.806 (0.769–0.843) | 0.893 (0.876–0.909) | 0.900 (0.890–0.910) | 0.907 (0.900–0.914) |
| SVM   | 0.806 (0.734–0.847) | 0.910 (0.893–0.927) | 0.907 (0.897–0.916) | 0.911 (0.904–0.917) |
| ANN   | 0.818 (0.781–0.856) | 0.911 (0.893–0.929) | 0.909 (0.900–0.918) | 0.913 (0.907–0.920) |

education level, have difficulties accessing medical care and tend to have more advanced disease stage at the time of presentation. All these factors are likely to impact their survival outcome. Concerning recurrence, one would expect patients in a private hospital to have lower odds of recurrence than patients in a public hospital. However, the patients in public hospitals showed lower odds of CRC recurrence. The only plausible explanation is that patients in private hospitals survive longer and experience recurrence than patients in public hospitals. This compliments our observed difference in survival between the private and public sectors because recurrence can only occur in patients that are alive.

Several studies [as discussed in a review by Wolpin and Mayer (37)] identified the benefit of treatment with chemotherapy (alone and/or in combination with surgery or radiation) to reduce the risk of CRC recurrence and mortality in some patients with specific risk groups. In our study, we pooled all the treatments with chemotherapy to create a new variable called “treatment with chemotherapy, yes/no”, irrespective of receiving any other treatment options. Besides, our predictive models were developed for all stages of CRC, with higher frequencies (65%) of the patients diagnosed with stages III and IV CRC. This study showed that intervention with chemotherapy was not helpful as the predictive model did not select this intervention as a factor indicating a favourable prognosis. This is reasonable, as such modalities are only employed in patients with an advanced CRC stage, which drives the poor outcomes. On the other hand, recurrence of CRC could be associated with several risk factors, including molecular sub-typing, stage of CRC, the primary site of CRC and treatment of co-morbidities (37, 38).

5. CONCLUSION

This study has certain limitations and strengths. We dropped 17 (2.4%) cases that were lost to follow-up in the survival models to avoid introducing bias to the estimations. Nonetheless, 71% of these cases were patients from public hospitals; hence, the exclusion of these patients should not alter the supposition that the private hospital had higher survival than public hospitals. In a future study using this data, we will predict the survival trend of these patients while incorporating censored cases in the analysis. Also, a future study using this data could explore the capabilities of other models not included in this study and disintegrate the CRC stages to uncover more trends within this population. This study strongly suggests that statistical algorithms should be concurrently used with ML algorithms to enhance global interpretation. We recommend that physicians should consider the important features noted in our findings when selecting promising therapeutic strategies. This type of study could stimulate the extrapolation of data collection outside of the hospitals because the variables that determine the outcome are as much to do with the pre-hospital detection of CRC patients as it is the treatment given to them by clinicians. We believe that this will be important for clinicians to grasp and engage in this type of study to embrace the precepts of primary health. Besides, the findings of this study will be beneficial to CRC researchers in other parts of the country. SA needs this level of data interpretation, especially in a circumstance where there is diversity and inequality in the country’s demographic landscape.

In conclusion, we have analysed a CRC study covering patients who visit both the private and public hospitals in the most populous city in SA. This study developed...
and internally validated the recurrence and survival prediction models for South African CRC patients. External validation of these models could have further affirmed the validity of this study. However, there is an ongoing framework for a prospective study to collect data for future validation of this study. The findings of this study form the basis for further studies on CRC in SA, using ML approaches. Also, this study can be generalised, not only to the population of CRC patients in SA but in other SSA countries with similar trends in urbanisation and dynamics in CRC epidemiology.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Human Research Ethics Committee (Medical) of the University of the Witwatersrand (M1911131). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

OA conceptualised, analysed the data, compiled the results, and wrote the manuscript. BB and JF provided the data and reviewed the manuscript. ES and GN reviewed the manuscript. MJCE and EM supervised the concept development and reviewed the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported through the DELTAS Africa Initiative. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and is supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Welcome Trust [grant 107754/Z/15/Z]. DELTAS Africa Sub-Saharan Africa Consortium for Advanced Biostatistics (SSACAB) programmer and the UK government. The authors also wish to thank the South African Medical Research Council WITS MRC CECRC for funding the CRCSA study.

**ACKNOWLEDGEMENTS**

We want to acknowledge the patients that participated in the CRCSA study and the staff of WDGMC that curated the database, especially Mrs Soneni Maphosa, for her valuable explanation of the study design and variables.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2021.694306/full#supplementary-material

**REFERENCES**

1. Favoriti P, Carbone G, Greco M, Pirozzi F, Emmanuele Maria Pirozzi R, Corcione F. Worldwide burden of colorectal cancer: a review. Updates surg. (2016) 68:7–11. doi: 10.1007/s13304-016-0359-y
2. Bebington B, Singh E, Fabian J, Jan Kruger C, Prodehl L, Surridge D, et al. Design and methodology of a study on colorectal cancer in Johannesburg, South Africa. JGH Open. (2018) 2:139–43. doi: 10.1002/jgh3.12061
3. Rawla R, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Front Gastroenterol. (2019) 14:89. doi: 10.5114/pg.2018.81072
4. The National Institute for Communicable Diseases (NICD). Cancer in South Africa 2014 Full Report 2014. (2017). Available online at: http://www.nicd.ac.za/centres/national-cancer-registry/cancer-statistics (accessed February 24, 2020).
5. Cruz JA, Wishart DS. Applications of machine learning in cancer prediction and prognosis. Cancer Inform. (2006) 2:59–77. doi: 10.1177/117693510600200030
6. Bose I, Mahapatra RK. Business data mining—a machine learning perspective. Inform Manag. (2001) 39:211–25. doi: 10.1016/S0378-7206(01)00091-X
7. Tollenaar N, Van der Heijden PGM. Which method predicts recidivism best?: a comparison of statistical, machine learning and data mining predictive models. J R Stat Soc Ser A. (2013) 176:565–84. doi: 10.1111/j.1467-985X.2012.01056.x
8. Nan K-J, Qin H-X, Yang G. Prognostic factors in 165 elderly colorectal cancer patients. World J Gastroenterol. (2003) 9:2207. doi: 10.3748/wjg.v9.i10.2207
9. Ting W-C, Angelu L-Y-C, Ho W-C, Cheewakriangkrai C, Chang H-R, Lin C-L. Machine learning in prediction of secondary primary cancer and recurrence in colorectal cancer. Int J Med Sci. (2020) 17:290. doi: 10.7150/ijms.37134
10. Bychkov D, Linder N, Turkki R, Nordling S, Kovanen PE, Verrill C, et al. Deep learning based tissue analysis predicts outcome in colorectal cancer. Sci Rep. (2018) 8:1–11. doi: 10.1038/s41598-018-21758-3
11. Noohi NA, Ahmadzadeh M, Fardaer M. Medical data mining and predictive model for colon cancer survivability. Int J Innovat Res Eng Sci. (2013) 2.
12. Gründer J, Prokosch H-U, Stürzl M, Croner R, Christoph J, Toddenroth D. Predicting Clinical Outcomes in Colorectal Cancer Using Machine Learning. Amsterdam: IOS Press BV (2018). p. 101–5.
13. Xu Y, Ju L, Tong J, Zhou CM, Yang J. Machine learning algorithms for predicting the recurrence of stage iv colorectal cancer after tumor resection. Scientific Reports. (2020) 10:1–9.
14. Takamatsu M, Yamamoto N, Kawachi H, Chino A, Saiito S, Ueno M, et al. Prediction of early colorectal cancer metastasis by machine learning using digital slide images. Comput Methods Programs Biomed. (2019) 178:155–61. doi: 10.1016/j.cmpb.2019.06.022
15. Stekhoven DJ, Bühlmann P. Missforest—non-parametric missing value imputation for mixed-type data. Bioinformatics. (2012) 28:112–8. doi: 10.1093/bioinformatics/btr597
16. Achilonu OJ, Fabian J, Musenge E. Modelling long-term graft survival with time-varying covariate effects: an application to a single kidney transplant centre in Johannesburg, South Africa. Front Public Health. (2019) 7:201. doi: 10.3389/fpubh.2019.00201
17. Velmurugan T, Anuradha C. Performance evaluation of feature selection algorithms in educational data mining. Int J Data Min Tech Appl. (2016) 5:131–9. doi: 10.20894/ijdmta.102.005.0 02.007
18. Pes B. Ensemble feature selection for high-dimensional data: a stability analysis across multiple domains. Neural Comput Appl. (2019) 32:9591–73. doi: 10.1007/s00521-019-04082-3
19. Tibshirani R. Regression shrinkage and selection via the lasso: a retrospective. J R Stat Soc Ser B. (2011) 73:273–82. doi: 10.1111/j.1467-9868.2011.00771.x
20. Breiman L. Random forests. Mach Learn. (2001) 45:5–32. doi: 10.1023/A:1010993404324
21. Rish I. An empirical study of the naive bayes classifier. In: IJCAI 2001 Workshop on Empirical Methods in Artificial Intelligence, Vol. 3, 41–46. (2001).
22. James G, Witten D, Hastie T, Tibshirani R. An Introduction to Statistical Learning. Vol. 112, New York, NY: Springer (2013).
23. Fine TL. Feedforward Neural Network Methodology. New York, NY: Springer Science & Business Media. (2006).
24. Ming C, Viassolo V, Probst-Hensch N, Chappuis PO, Dinov ID, Katapodi MC. Machine learning techniques for personalized breast cancer risk prediction: comparison with the bcrt and bosdicea models. Breast Cancer Res. (2019) 21:75. doi: 10.1186/s13058-019-1158-4
25. Streyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for some traditional and novel measures. Epidemiology. (2010) 21:128. doi: 10.1097/EDE.0b013e3181c06f2
26. Bui DT, Tuan TA, Klempke H, Pradhan B, Revhaug I. Spatial prediction models for shallow landslide hazards: a comparative assessment of the efficacy of support vector machines, artificial neural networks, kernel logistic regression, and logistic model tree. Landslides. (2016) 13:361–378. doi: 10.1007/s10346-015-0557-6
27. Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med. (2004) 66:411–21. doi: 10.1097/00006842-200405000-00021
28. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. Springer Science & Business Media. (2009).
29. Raschka S. Model, model selection, and algorithm selection in machine learning. arXiv [Preprint]. arXiv:1811.12808. (2018).
30. Dreiselt S, Ohno-Machado L. Logistic regression and artificial neural network classification models: a methodology review. J Biomed Inform. (2002) 35:352–9. doi: 10.1016/S1532-0464(03)00034-0
31. Jie MA, Collins GS, Steyerberg EW, Verbakel JY, van Calster B. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. J Clin Epidemiol. (2019) 10:12–22. doi: 10.1016/j.jclinepi.2019.02.004
32. Zare-Bandamiri M, Fararouei M, Zohourinia S, Daneshi N, Dianatinasab M. Risk factors predicting colorectal cancer recurrence following initial treatment: a 5-year cohort study. Asian Pac J Cancer Prev. (2017) 18:2465. doi: 10.22034/APJCP.2017.18.9.2465
33. Steele SR, Park GE, Johnson EK, Martin MJ, Stojadinovic A, Maykel JA, et al. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. Dis Colon Rectum. (2014) 57:303–310. doi: 10.1097/DCR.0b013e3182a568c7
34. Chou CL, Chang SC, Lin TC, Chen WS, Jiang JK, Wang HS, et al. Differences in clinicopathological characteristics of colorectal cancer between younger and elderly patients: an analysis of 322 patients from a single institution. Ann J Surg. (2011) 202:574–82. doi: 10.1016/j.amjsurg.2010.10.014
35. Stojadinovic A, Bilchik A, Smith D, Eberhardt JS, Ward EB, Nissan A, et al. Clinical decision support and individualized prediction of survival in colon cancer: Bayesian belief network model. Ann Surg Oncal. (2013) 20:161–74. doi: 10.1097/s10434-012-2555-4
36. Brand M, Gaylard P, Ramos J. Colorectal cancer in south africa: An assessment of disease presentation, treatment pathways and 5-year survival. South Afr Med J. (2018) 108:118–22. doi: 10.7196/SAMJ.2018.v108i2.12338
37. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. (2008) 134:1296–1310. doi: 10.1053/j.gastro.2008.02.098
38. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ace inhibitors on the risk for breast cancer recurrence: results from the lace cohort. Breast Cancer Res Treat. (2011) 129:549–56. doi: 10.1007/s10549-011-1505-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Achilonu, Fabian, Bebington, Singh, Eijkemans and Musenge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.